Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)
收藏数据链接：
官方服务：
资源简介：
Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.
提供机构：
figshare创建时间：
2021-04-16
